Evaluating the validity of animal models for research into therapies for immune-based disorders.
The last few decades of the 20th century have shown an intensified search for safer and more effective medications against chronic diseases that burden ageing societies of the western world. The impressive development of biotechnological production techniques has greatly facilitated the pharmaceutical development of relatively non-toxic biological molecules. However, despite the huge investments, only a few effective therapies for immune-based diseases have reached the clinic. In this article we use examples from monoclonal antibody trials to discuss the validity and predictive strength of the animal models currently used for the development of effective therapies.
't Hart
Bert A
BA
Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, The Netherlands. hart@bprc.nl
Amor
Sandra
S
Jonker
Margreet
M
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy / Q000276:immunology; D007154:Immune System Diseases / Q000276:immunology / Q000628:therapy*; D007167:Immunotherapy / Q000379:methods; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology; D016377:Organ Transplantation
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal